Screener
Tango Therapeutics TNGX Total Revenue
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Collaboration revenue | — | $5,392 |
| Operating expenses: | ||
| Research and development | 33,534 | 36,442 |
| General and administrative | 15,235 | 11,480 |
| Total operating expenses | 48,769 | 47,922 |
| Loss from operations | (48,769) | (42,530) |
| Other income: | ||
| Interest income | 2,177 | 1,614 |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's total revenue?
- Tango Therapeutics (TNGX) reported total revenue of $0 in Q1 2026.
- How has Tango Therapeutics's total revenue changed year-over-year?
- Tango Therapeutics's total revenue decreased by 100.0% year-over-year, from $5.39M to $0.
- What is the long-term trend for Tango Therapeutics's total revenue?
- Over 4 years (2021 to 2025), Tango Therapeutics's total revenue has grown at a 13.9% compound annual growth rate (CAGR), from $37.04M to $62.38M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Tango Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude